Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.